Dr. Helen Mitchell obtained her PhD from the University of California, San Diego, where she completed the total synthesis of a powerful antibiotic called Everninomicin 13,384-1. Dr. Mitchell continued in the field of organic synthesis during her postdoctoral fellowship at the Scripps Research Institute, where she worked on the total synthesis of other natural products. She joined Merck Research Labs at West Point in July of 2001 and worked on several nuclear receptor programs for the treatment of osteoporosis, cancer and inflammatory diseases. She subsequently worked on several programs to target pain and contributed to two drugs for the treatment of migraine. She has held various roles including management of CRO resources and expansion of parallel methods and data analysis.  Currently, Dr. Mitchell is director of the Technology Enabled Chemistry Group and manages the parallel medicinal chemistry and high-throughput purification groups at West Point.